Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

Peter Voorhees, MD
Published: Wednesday, Jul 12, 2017



Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

It is likely that the addition of daratumumab (Darzalex) to the lenalidomide (Revlimid)/dexamethasone backbone will lead to a significant progression-free and overall survival benefit for patients with multiple myeloma, Voorhees explains. This regimen is also associated with high response rates. In a study with this regimen in the relapse setting, at least three-fourths of patients achieved a very good partial response and a little over 40% achieved a complete response or better, he adds. These numbers will likely be higher in newly diagnosed disease.

The addition of elotuzumab (Empliciti) and ixazomib (Ninlaro) to the field are overall well tolerated agents that provide additional options for patients.
SELECTED
LANGUAGE


Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

It is likely that the addition of daratumumab (Darzalex) to the lenalidomide (Revlimid)/dexamethasone backbone will lead to a significant progression-free and overall survival benefit for patients with multiple myeloma, Voorhees explains. This regimen is also associated with high response rates. In a study with this regimen in the relapse setting, at least three-fourths of patients achieved a very good partial response and a little over 40% achieved a complete response or better, he adds. These numbers will likely be higher in newly diagnosed disease.

The addition of elotuzumab (Empliciti) and ixazomib (Ninlaro) to the field are overall well tolerated agents that provide additional options for patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x